A high-stakes disease. Bladder cancer is the 10th most common cancer worldwide, with around 500,000 new cases and 200,000 deaths per year. About 25% of patients have muscle-invasive bladder cancer (MIBC), a form with poor prognosis and five-year survival below 50% even after radical surgery. Selecting the right treatment for each patient at each stage of disease is critical.
The standard treatment for MIBC is radical cystectomy (bladder removal), ideally preceded by cisplatin-based neoadjuvant chemotherapy for eligible patients. Immunotherapy using immune checkpoint inhibitors has more recently emerged as a major treatment option, particularly for patients who cannot tolerate cisplatin or who relapse after surgery.
Traditional imaging for bladder cancer relies on CT and MRI, but 18F-FDG PET/CT -- a scan that images both anatomy and cancer metabolism simultaneously -- offers a different kind of information. Bladder cancer cells overexpress glucose transporters and consume glucose at elevated rates, making them visible on FDG PET. This review synthesizes evidence for how this technology can guide personalized decisions at every stage of MIBC management.
Distant metastasis detection is the strongest suit. While FDG PET/CT has limited value for detecting the primary bladder tumor itself -- because the radiotracer is excreted in urine, creating artifact -- its greatest strength is in detecting disease that has spread beyond the bladder. In patient-based analyses, PET/CT sensitivity for distant metastases ranges from 54% to 87%, with specificity from 90% to 97%. One study found PET/CT more sensitive than CT alone for distant metastases (54% versus 41%), while both maintained high specificity.
PET/CT changed clinical management in 18% to 68% of patients compared to conventional imaging alone, and resulted in fewer additional tests in 70% of patients. The presence of FDG-avid regional lymph nodes or extrapelvic lesions was independently predictive of overall survival, while the same findings on conventional CT were not statistically significant. This means PET/CT findings carry prognostic information that pure anatomy cannot capture.
For lymph node staging, a meta-analysis of 14 studies in 785 patients found pooled sensitivity of 57% and specificity of 92% for pelvic lymph node detection. Pooled data from studies comparing CT alone to PET/CT show that PET/CT identifies nodal disease in about 52% of truly node-positive patients versus only 38% for CT. A key clinical application is ruling out nodal metastasis in enlarged lymph nodes that are FDG-negative, potentially avoiding unnecessary treatment escalation.
An important consensus statement concluded that FDG PET/CT is the imaging modality of choice for avoiding over-treatment in oligometastatic patients, with 88% agreement among participating experts. When conventional imaging identifies only a single metastatic site (oligometastatic disease), PET/CT often reveals additional lesions that would change the treatment approach.
Response assessment during neoadjuvant chemotherapy. FDG PET/CT has demonstrated 75% sensitivity and 90% specificity for identifying patients who achieve complete pathologic response to neoadjuvant chemotherapy -- meaning no residual cancer is found in the surgically removed bladder. For monitoring lymph node response during induction chemotherapy, PET/CT distinguishes responders from non-responders with sensitivity of 83% to 100% and specificity of 67% to 94%, outperforming conventional CT (sensitivity 88%, specificity only 33%).
In the metastatic setting, FDG PET/CT using EORTC metabolic response criteria outperformed CT interpretation using standard RECIST anatomic criteria for predicting response to first-line chemotherapy with cisplatin and gemcitabine. Early PET/CT assessment after just two cycles of MVAC chemotherapy predicted both progression-free survival and overall survival, suggesting it can rapidly identify patients who are not benefiting from treatment.
Immunotherapy has introduced new patterns of apparent tumor behavior that complicate response assessment. Pseudo-progression -- where tumors appear to grow before shrinking -- occurs in 1.5% to 17% of bladder cancer patients on immunotherapy. Hyperprogression -- a rapid acceleration in tumor growth exceeding twice the expected rate -- occurs in about 9% of solid tumor patients on anti-PD-1 and anti-PD-L1 agents. FDG PET/CT is uniquely positioned to distinguish these patterns from true progression, though specific criteria for bladder cancer remain under development.
A particularly valuable application of PET/CT during immunotherapy is the detection of immune-related adverse events. These treatment side effects can involve almost any organ system, including the lungs, thyroid, pituitary gland, colon, joints, and pancreas. PET/CT can detect these adverse events with 83% accuracy, often revealing them before they become clinically severe. In bladder cancer patients on immunotherapy, immune-related adverse events occur in up to 23% of patients.
High performance for post-treatment surveillance. After radical cystectomy and/or systemic chemotherapy, FDG PET/CT performs well for detecting disease relapse. Reported sensitivity ranges from 87% to 92% and specificity from 83% to 94% for recurrence detection. Critically, PET/CT findings led to a significant change in management in up to 40% of patients compared to conventional imaging alone.
Specific PET-derived metrics also carry prognostic value in the recurrent disease setting. SUVmax (maximum standardized uptake value, a measure of the most metabolically active part of a tumor) greater than 6, and total lesion glycolysis (a measure of total metabolic activity accounting for both intensity and volume) greater than 8.5, were the most significant predictors of two-year progression-free survival in recurrent bladder cancer.
These findings support using FDG PET/CT not only to detect recurrence but also to stratify patients by expected outcome at the time of recurrence detection -- potentially guiding decisions about treatment intensity, eligibility for clinical trials, or palliative versus curative intent management.
The urine problem and how to address it. The fundamental challenge of FDG PET/CT in bladder cancer is that the radiotracer is excreted through the kidneys into the urine, creating intense radioactivity in the bladder that can mask adjacent pelvic structures. Standard protocols require adaptation specifically for bladder cancer applications.
The recommended approach for bladder cancer PET/CT includes forced diuresis -- intravenous furosemide (20 to 40 mg) combined with oral hyperhydration (1.5 to 2 liters of water) -- to dilute and flush radioactive urine from the bladder before pelvic imaging. Supplementary delayed pelvic images may be added for inconclusive standard results. These protocols significantly improve the ability to evaluate pelvic lymph nodes adjacent to the radioactive urine-filled bladder.
Early dynamic PET acquisitions, performed before radioactive urine fills the bladder, have also been explored. These proof-of-concept studies suggest improved tumor conspicuity by increasing the tumor-to-urine signal ratio, though impact on lymph node staging has not yet been evaluated. Modern PET technology featuring three-dimensional acquisition, time-of-flight reconstruction, and point-spread-function correction has also significantly improved image quality and the ability to detect subcentimeter disease foci.
Combining the best of both worlds. MRI is currently the most accurate imaging modality for local bladder staging, with 92% to 98% accuracy for detecting muscle invasion. However, MRI struggles with lymph node staging (sensitivity remains relatively low even with functional sequences like diffusion-weighted imaging). PET/CT excels at distant metastasis detection. Combining them in a simultaneous PET/MRI scanner theoretically offers the best of both.
In a prospective pilot study of 24 patients, PET/MRI showed accuracy of 95% for pelvic lymph node involvement versus 76% for MRI alone, and 100% versus 91% for detecting extravesical pelvic involvement. However, another pilot study after neoadjuvant chemotherapy in 18 patients showed inconsistent results, highlighting that the evidence base remains small and further prospective validation is needed.
Alternative PET tracers have also been studied to avoid the urine-artifact problem: 11C-acetate, 11C-choline, and 18F-sodium fluoride. None have demonstrated sufficient improvement over standard FDG PET/CT to justify routine clinical use. Sodium fluoride PET/CT did show superiority to standard bone scintigraphy for detecting bone metastases, representing one potential niche application.
Mining images for hidden information. A major emerging application is using artificial intelligence (AI) techniques including radiomics and deep learning to extract quantitative features from PET/CT images that are invisible to human readers. Radiomics involves converting medical images into thousands of mathematical descriptors of tumor shape, texture, and metabolic pattern, which can then be linked to pathology findings or clinical outcomes.
While no published studies had yet applied AI specifically to FDG PET images in bladder cancer at the time of this review, promising results using CT and MRI radiomics had been published for predicting invasion depth, tumor grade, lymph node staging, and treatment response. AI applied to PET/CT in other cancers had already demonstrated value for predicting nodal disease, risk stratification, treatment response, and patient outcomes.
The key advantage of AI-based analysis is reproducibility: whereas physician image interpretation is inherently subjective and variable between readers and institutions, an AI algorithm applies identical analytical rules to every scan. AI can also identify patterns across thousands of features simultaneously, potentially detecting prognostic signals that no human reader would notice from visual inspection alone.
The authors envision a future in which clinical, biological, molecular, and imaging data -- including FDG PET metrics -- are integrated by AI systems to generate patient-specific treatment recommendations, representing a genuine paradigm shift toward data-driven precision medicine in bladder cancer. Prospective studies validating this approach are urgently needed.
A promising but still evolving tool. The review concludes that evidence supporting FDG PET/CT across the management of muscle-invasive bladder cancer is growing. PET/CT outperforms or meaningfully complements conventional imaging for multiple tasks, with the strongest evidence for initial staging of oligometastatic patients and detection of distant metastases.
There is growing consensus that FDG PET/CT should guide management decisions when patients are considered oligometastatic by conventional imaging alone, a clinical scenario where identifying additional lesions can meaningfully change treatment intent. However, prospective high-evidence studies remain scarce, preventing formal adoption into consensus guidelines from major organizations.
The combination of improved PET/CT technology, validated diuresis protocols, emerging PET/MRI platforms, AI-based image analysis, and a shifting treatment landscape including immunotherapy creates an environment where FDG PET/CT's role in bladder cancer management is expected to expand substantially over the coming decade.